Previous 10 | Next 10 |
BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the second q...
2023-06-29 10:10:59 ET Gainers: RenovoRx ( RNXT ) +37% . Immunome ( IMNM ) +36% . DermTech ( DMTK ) +15% . Galera Therapeutics ( GRTX ) +9% . Oncolytics Biotech ( ONCY ) +7% . Losers: BioXcel Therapeutics ( BTA...
2023-06-29 08:47:24 ET BioXcel Therapeutics ( BTAI ) -67% . announces positive topline results from TRANQUILITY II phase 3 trial of BXCL501 for acute treatment of alzheimer’s disease-related agitation . CorMedix ( CRMD ) -21% on pricing $40M securities off...
Minerva Neurosciences, Inc. (NASDAQ: NERV) is one of today's top gainers. The company's shares are currently up 51.16% on the day to $9.1. Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the tre...
2023-06-28 10:09:16 ET Gainers: Minerva Neurosciences ( NERV ) +51% . Regional Health Properties ( RHE ) +12% . Genfit ( GNFT ) +11% . RenovoRx ( RNXT ) +11% . OPKO Health ( OPK ) +5% . Losers: Cognition Therapeutics ( C...
2023-06-28 08:57:07 ET Biopharmaceutical company Minerva Neurosciences ( NASDAQ: NERV ) said on Wednesday that it is launching an ~$20M private investment in public equity, or PIPE, financing. The financing involves 1.43M shares at $10 per share and pre-funded warrants to...
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it has agreed to sell an aggregate of 1,425,000 s...
2023-05-19 17:34:30 ET Summary NERV has once again run on the submission of an NDA for roluperidone for the treatment of negative symptoms in schizophrenia. There will be no Refusal to File letter this time, with NERV using a dispute resolution process to its advantage. No adv...
2023-05-15 11:26:05 ET Minerva Neurosciences, Inc. (NERV) Q1 2023 Earnings Conference Call May 15, 2023, 8:30 AM ET Company Participants Geoff Race - President Dr. Remy Luthringer - Executive Chairman and CEO Fred Ahlholm - Senior Vice President and CFO Con...
2023-05-15 07:38:20 ET Minerva Neurosciences press release ( NASDAQ: NERV ): Q1 GAAP EPS of -$1.31. Cash, cash equivalents, and restricted cash as of March 31, 2023 were approximately $36.1 million, compared to $36.2 million as of December 31, 2022. For further detai...
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
Candel Therapeutics, Inc. (NASDAQ: CADL) announced overall survival data from a phase II study evaluating its lead investigational adenovirus immun...
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...